[
  {
    "ts": null,
    "headline": "Boston Scientific Corp. stock underperforms Wednesday when compared to competitors",
    "summary": "Boston Scientific Corp. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=34743edb2c8808675256e36310cb84a0db7f9028240521a25fc924904549f8fc",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770827940,
      "headline": "Boston Scientific Corp. stock underperforms Wednesday when compared to competitors",
      "id": 139062755,
      "image": "",
      "related": "BSX",
      "source": "MarketWatch",
      "summary": "Boston Scientific Corp. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=34743edb2c8808675256e36310cb84a0db7f9028240521a25fc924904549f8fc"
    }
  },
  {
    "ts": null,
    "headline": "The Top 5 Analyst Questions From Boston Scientific’s Q4 Earnings Call",
    "summary": "Boston Scientific’s fourth quarter results were met with a significant negative market reaction, despite meeting revenue expectations and delivering adjusted earnings above analyst consensus. Management pointed to broad-based growth, with electrophysiology (EP), WATCHMAN, interventional oncology, and neuromodulation cited as standouts. However, concerns emerged around sequential stagnation in U.S. EP sales and a modest miss in U.S. WATCHMAN, both key franchises for Boston Scientific’s ongoing mo",
    "url": "https://finnhub.io/api/news?id=fd6a9ea2099f0005561e1c3d53328735c6e9590335ca713d0a48e9cad66fad1a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770788507,
      "headline": "The Top 5 Analyst Questions From Boston Scientific’s Q4 Earnings Call",
      "id": 139042348,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific’s fourth quarter results were met with a significant negative market reaction, despite meeting revenue expectations and delivering adjusted earnings above analyst consensus. Management pointed to broad-based growth, with electrophysiology (EP), WATCHMAN, interventional oncology, and neuromodulation cited as standouts. However, concerns emerged around sequential stagnation in U.S. EP sales and a modest miss in U.S. WATCHMAN, both key franchises for Boston Scientific’s ongoing mo",
      "url": "https://finnhub.io/api/news?id=fd6a9ea2099f0005561e1c3d53328735c6e9590335ca713d0a48e9cad66fad1a"
    }
  }
]